

## References

### M-18

1. Hayes, Inc. Hayes Comparative Effectiveness Review. *Hybrid Maze Procedure for Atrial Fibrillation*. Lansdale, PA; Hayes, Inc.; 07/15/2019.
2. Alturki A, Proietti R, Dawar A, Alturki H, Huynh, Essebag V. Catheter ablation for atrial fibrillation in heart failure with reduced ejection fraction: A systematic review and meta-analysis of randomized controlled trials. *BMC Cardiovasc Disorder*. 2019;19:18.
3. Asad ZUA, Yousif A, Khan MS, et al. Catheter ablation versus medical therapy for atrial fibrillation: A systematic review and meta-analysis of randomized controlled trials. *Circ Arrhythm Electrophysiol*. 2019;12(9):e007414.
4. Marrouche NF, Brachmann J, Andresen D, et al. Catheter ablation for atrial fibrillation with heart failure. *N Engl J Med*. 2018;378(5):417-427.
5. Su W, Orme GJ, Hoyt R, et al. Retrospective review of Arctic Front Advance Cryoballoon Ablation: A multicenter examination of second-generation cryoballoon (RADICOL trial). *J Interv Card Electrophysiol*. 2018;51(3):199-204.
6. Kuck KH, Merkely B, Zahn R, et al. Catheter ablation versus best medical therapy in patients with persistent atrial fibrillation and congestive heart failure: The randomized AMICA trial. *Circ Arrhythm Electrophysiol*. 2019;12(12):e007731.
7. Packer DL, Mark DB, Robb RA, et al. Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: The CABANA randomized clinical trial. *JAMA*. 2019;321(13):1261-1274.
8. Mark DB, Anstrom KJ, Sheng S, et al. Effect of catheter ablation vs medical therapy on quality of life among patients with atrial fibrillation: the CABANA randomized clinical trial. *JAMA*. 2019;321(13):1275-1285.
9. Blomström-Lundqvist C, Gizurarson S, Schwieler J, et al. Effect of catheter ablation vs antiarrhythmic medication on quality of life in patients with atrial fibrillation: The CAPTAF randomized clinical trial. *JAMA*. 2019;321(11):1059-1068

10. Nielsen JC, Johannessen A, Raatikainen P, et al. Long-term efficacy of catheter ablation as first-line therapy for paroxysmal atrial fibrillation: 5-year outcome in a randomised clinical trial. *Heart*. 2017;103(5):368-376.
11. Calkins H, Hindricks G, Cappato R, et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. *Europace*. 2018;20(1): e1-e160.
12. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. *J Am Coll Cardiol*. 2019;74(1):104-132.
13. Zhang D, Shi J, Quan H, et al. Five-year results of a modified left atrial maze IV procedure in the treatment of atrial fibrillation: A randomized study. *ANZ J Surg*. 2020;90(4):602-607.
14. Castella M, Kotecha D, van Laar C, et al. Thoracoscopic vs. catheter ablation for atrial fibrillation: Long-term follow-up of the FAST randomized trial. *Europace*. 2019;21(5):746-753.
15. Adiyaman A, Buist TJ, Beukema RJ, et al. Randomized Controlled Trial of Surgical Versus Catheter Ablation for Paroxysmal and Early Persistent Atrial Fibrillation. *Circ Arrhythm Electrophysiol*. 2018;11(10):e006182.
16. Vos LM, Bentala M, Geuzebroek GS, et al. Long-term outcome after totally thoracoscopic ablation for atrial fibrillation. *J Cardiovasc Electrophysiol*. 2020;31(1):40-45.
17. Badhwar V, Rankin JS, Damiano RJ, et al. The Society of Thoracic Surgeons 2017 Clinical Practice Guidelines for the Surgical Treatment of Atrial Fibrillation. *Ann Thorac Surg*. 2017;103(1):329-341.
18. Ad N, Damiano RJ, Badhwar V, et al. Expert consensus guidelines: Examining surgical ablation for atrial fibrillation. *J Thorac Cardiovasc Surg*. 2017;153(6):1330-1354.e1.
19. InterQual® Level of Care Criteria 2019. Acute Care Adult. Change Healthcare, LLC.

20. Moss JD, Flatley EE, Beaser et al. Jeevanandam V, Uriel N, Tung R. Characterization of ventricular tachycardia after left ventricular assist device implantation as destination therapy: a single-center ablation experience. *JACC: Clin Electrophysiol.* 3(12):1412-24.
21. Vergara P, Tzou WS, Tung R, Brombin C, et al. Predictive score for identifying survival and recurrence risk profiles in patients undergoing ventricular tachycardia ablation: The I-VT score. *Circulation: Arrhythm Electrophysiol Rev.* 2018;(12):e006730.
22. Andrade JG, Wells GA, Deyell MW, et al. Cryoablation or drug therapy for initial treatment of atrial fibrillation. *N Engl J Med.* 2021;384(4):305-315.
23. Wazni OM, Dandamudi G, Sood N, et al. Cryoballoon ablation as initial therapy for atrial fibrillation. *N Engl J Med.* 2021;384(4):316-324.
24. Kuck KH, Lebedev DS, Mikhaylov EN, et al. Catheter ablation or medical therapy to delay progression of atrial fibrillation: The randomized controlled atrial fibrillation progression trial (ATTEST). 2021;23(3):362-369.
25. Haldar S, Khan HR, Boyalla V, et al. Catheter ablation vs. thoracoscopic surgical ablation in long-standing persistent atrial fibrillation: CASA-AF randomized controlled trial. *Eur Heart J.* 2020;41(47):4471-4480.
26. DeLurgio DB, Crossen KJ, Gill J, et al. Hybrid convergent procedure for the treatment of persistent and long-standing persistent atrial fibrillation: Results of converge clinical trial. *Circ Arrhythm Electrophysiol.* 2020;13(12):e009288.
27. Maclean E, Yap J, Saberwal B, et al. The convergent procedure versus catheter ablation alone in longstanding persistent atrial fibrillation: A single centre, propensity-matched cohort study. *Int J Cardiol.* 2020;303:49-53.
28. Tonks R, Lantz G, Mahlow J, et al. Short and intermediate term outcomes of the convergent procedure: Initial experience in a tertiary referral center. *Ann Thorac Cardiovasc Surg.* 2020;26(1):13-21.